Shares of
TriMas Corporation (
TRS - Free Report) surged around 28% over the last year driven by improved results aided by its focus on leveraging the TriMas Business Model as well as improved market conditions. Going forward, a strong pipeline of both product and process innovation will propel growth. Moreover, the company has fared better than the
industry’s decline of 12%.
The company has a market cap of $1.4 billion. Over the past three months, its average volume of shares traded has been approximately 109K.
Further, TriMas surpassed the Zacks Consensus Estimate in two of the trailing four quarters, registering an average positive earnings surprise of 2.28%.
The packaging segment, the company’s most profitable business, is likely to benefit from new products and realignment of the segment’s manufacturing footprint. The company is developing its global marketing and salesforce to better align with end-markets and customers.
TriMas Corporation Price
Upward Estimate Revisions
TriMas' positive estimate revisions reflect analyst optimism on the company's potential as earnings growth is often an indication of robust prospects. Estimates for the company moved up over the past 60 days, reflecting analysts' bullish sentiments. The earnings estimate for 2018 has gone up 2.4% while the estimate for 2019 has gone up 2.2%.
The above-mentioned tailwinds have raised investors' optimism in the stock. Consequently, it is anticipated to drive the company's share price in the days ahead.
Other Stocks to Consider
Some other top-ranked stocks in the same space include W.W. Grainger, Inc. (
GWW - Free Report) , Lawson Products, Inc. and Atkore International Group Inc. (
ATKR - Free Report) . All the three stocks sport a Zacks Rank #1.
Grainger has a long-term earnings growth rate of 12.5%. Its shares have appreciated 132%, over the past year.
Lawson Products has a long-term earnings growth rate of 17.5%. The company’s shares have gained 42% in a year’s time.
Atkore International has a long-term earnings growth rate of 10%. The stock has rallied 70% in a year’s time.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on GWW - FREE
Get the latest research report on TRS - FREE
Get the latest research report on ATKR - FREE